This was originally published on June 3, 2013, and it continues to be one of the most-discussed topics we’ve covered during those years. The idea continues to be teased and promoted actively by Tom Dyson and his folks at Palm Beach Letter, sometimes using different names, so we’re re-posting it for those new readers who […]
Articles
- Most Relevant
- Most Recent
Today we take a gander at a pitch from Mark Skousen, who has been a newsletter guy for decades with his Forecasts & Strategies newsletter (he’s also an itinerant economics professor, and runs the big “freedomfest” conference in Las Vegas each year, among other things). And the headline of his latest “presentation” pretty well sums […]
I’ll open today by saying that I don’t know if the euro will rise or fall against the dollar over the next two years. And neither does anyone else. Global currency markets are vast and complex and driven by trader sentiment and economic growth and interest rates and unpredictable crises and lots of other influences. […]
Oxidation for Health…Physical and Fiscal[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Here we are, solidly in the postmodern 21st century, “so late in the goddam day,” as one of novelist Martin Amis’s characters says, and what […]
“One unique type of gold investment (that most Americans have never heard of) based in British Columbia has outperformed every asset class in existence – rising twice as fast as gold. “The average investor in this gold secret made over 80% a year for 20 straight years – even after gold crashed last year. “But […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for our Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Visit his Stock Gumshoe page for more.] Bacteria are prokaryotes. Animal cells, fungi and plants are eukaryotes. Prokaryotes tend to be acellular and […]
OK, OK, the questions on this one are getting a bit overwhelming — and I’m afraid that if I don’t cover this one soon the villagers will soon be gathering their fiery torches and marching on Castle Gumshoe … so here goes. Louis Basenese and the folks at Wall Street Daily are pitching his MicroCap […]
This ad sounds a little bit like a very popular one we looked at a few months back — then, it was for $1 “Silver Shots”, and it was a teaser for a leveraged derivative trade on silver futures (or, in plainer speak, it was for long-term call options on the SLV ETF). If you […]
We’ve got a good teaser to solve today, but first — a quick plea: This will be our final week of “Gumshoe Gives Back” this year — we will be donating at least half of all the membership contributions received through the rest of this week (until the end of the day on Friday, 12/12) […]
The latest ad from Teeka Tiwari for the Palm Beach Letter is pushing the idea that you can somehow collect some incredible monthly income with an “off the books” retirement income source… here’s how it’s introduced: “Now, For the First Time Ever, a Former Wall Street Hedge Fund Manager Reveals How You Can Unlock the […]
This teaser solution was originally posted on October 5, 2016 — the ad has circulated very heavily at various times in the past 18 months, routinely driving a lot of questions our way, so I took another look in May of 2017 when the ad was last updated. The ad still carries the May, 2017 […]
This Friday File article was originally released to the Irregulars on June 16, we have now opened it up for anyone to read in hopes of answering some questions that continue to roll in about the latest Biotech Insider Alert ads. The text below has not been updated or revised, though I and other readers […]
Porter Stansberry is probably the best marketer out there in the financial newsletter world, and has access to the biggest email lists both within his company and in partnership with all of Agora’s other subsidiaries and affiliates… so when one of his ideas or letters gets a big marketing push, it tends to have a […]
OK, so this one’s a bit tricky. And not just because the clues are a bit limited. Don’t worry, we’ll still find an answer for you … but a caveat or two first … Frank Curzio edits Phase 1 Investor, which is Stansberry’s “big ticket” newsletter that typically covers small tech, biotech and natural resources […]
“I Have Access to Financial Strategies That You Don’t Have… “And They Could Be Worth a Fortune “Starting with the Next 295% Extravaganza… “I just discovered a large, sudden and concentrated block of insider buying. “Please… pay attention to this… “I’m talking about 7 insiders, including the CEO and CFO. They just spent $353,000 on […]
If there’s one asset class that attracts individual investors like lemmings every time it hits a new high, it’s gold. And if there’s one thing that newsletter publishers know, it’s to sell the people what they want … whether they know they want it or not. So today we’ve got a new high in the […]
This pitch about “Federal Rent Checks” has been circulating for quite a while, and it’s still being mailed out with a July 2018 date under the signature (I got a few questions about it just this week), so I decided to take a second look. And what do you know, there has been a LOT […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, he […]
I was reading earlier today about Porter Stansberry’s aggressive short bet against the computer hard drive makers, who seem to have been the canaries in the coal mine regarding computer sales for several years — and at the same time I received a teaser from Louis Navellier for his Blue Chip Growth teasing that the […]
This latest pitch coming through from the Wealth Daily folks, for Jimmy Mengel’s The Crow’s Nest advisory, has caught the attention of plenty of Gumshoe readers — it starts with a long spiel about tapping into the “secret” holdings of billionaires by using a SEC disclosure rule that these rich folks are all fighting tooth […]
Earlier this week, when I was looking into Teeka Tiwari’s pitch about stealing from Vladimir Putin, I promised that I’d follow up and look at the gold investment he was also teasing in that letter… so let’s get to it! His overall spiel is selling something he calls the “New Cold War Playbook” as a […]
A new study Push Telecommunications for Tele-Medicine (PTT) and M-Health: Market Shares, Strategy, and Forecasts, Worldwide, 2015 to 2021. The 2015 study has 815 pages, 259 tables and figures. Worldwide markets are poised to achieve significant growth as the push systems are used inside telemedicine systems and m-health apps to move patient and clinician communication […]
This microblog is not for a discussion of stocks – it’s for telling fellow Gummies and Gummie-esses about WEB SITES THAT HAVE SOMETHING TO DO WITH INVESTING that you find useful. To start with, http://www.macrotrends.net/ has 60 historical charts ranging from topics like …..A Gold to Oil Ratio Historical Chart ….tracks the ratio of the […]
This microblog is for stocks that do not fit neatly in http://www.stockgumshoe.com/2015/04/microblog-biotech-in-a-dr-kss-less-world/ or http://www.stockgumshoe.com/2015/04/microblog-biotech-by-hendrixnuzzles/. To get started, Thomas Kelly mentioned NVIV on the “……by-hendrixnuzzles blog “: “…. The Neuro-Spinal Scaffold is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion. The Neuro-Spinal Scaffold provides […]
BIOTECH IN A Dr. KSS-LESS WORLD Welcome! The purpose of this thread will be to discuss, identify and follow small or mid-cap biotechs that have credible scientific platforms , big potential target markets, favorable qualified second party medical opinion, and significant stock appreciation potential in a one-to-three year time horizon; and to create and track […]
This thread is designed to allow Irregulars to discuss, share and provide input for calender catalyst events, primarily but not limited to equities contained on the Green Tab of the KSS Da Man! spreadsheet that is maintained by Hi Pockets. The calender currently can be updated only by Benny, Lawrence, Dr. KSS and myself. The […]
I thought this was going to be another pitch for what’s lately been teased very aggressively as invisible “770 Account” participating whole life insurance by the Palm Beach Folks… so I almost tossed the email (there are only so many times you can run through that story). But this is a little bit different — […]
This article originally appeared on January 28, 2015, when the ad was newly released — the same ad, without any major revisions that we noticed, is being distributed widely again and generating questions, so we make this piece available again. The stock teased is at roughly the same price now as it was on January […]
Antibiotic resistance is a big deal, as you undoubtedly already know — and resistant strains of various cooties are becoming more and more of a problem, particularly in hospital settings where they seem to spread like wildfire among the sick, infirm and open-wounded, but elsewhere as well. And the new wave of antibiotics is certainly […]
“I firmly believe that if the whole materia medica could be sunk to the bottom of the sea, it would be all the better for mankind and all the worse for the fishes.” — Oliver Wendell Holmes, M. D., Professor of Medicine , Harvard “With all his conscience and one eye askew, So false he […]
[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe,” is a medical writer (not a doctor) who shares his thoughts with our readers a couple times a month. He does not generally cover investing topics, but I find his discussions of broader health issues interesting and useful. Enjoy!] Doc Gumshoe would not be […]
Just returning from vacation, and I don’t have anything new for you just yet… but I see that the questions have been piling up about Frank Curzio’s new newsletter and the $1 gold stock he’s been touting as they drum up new subscribers. And, thankfully, that’s one I already took a quick look at — […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Enjoy!] It could be the premise of a tawdry unrated movie that teenage boys sneak glimpses of on Netflix when they’re home alone. […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] His tidily rhyming names perhaps destined him for fame. While Jack Kerouac’s work and popularity were before my time, his cultural and literary restlessness assure him […]
I like Frank Curzio’s podcast (now called Wall Street Unplugged), and I generally find his way of thinking interesting, so after he was laid off by Porter Stansberry I was half hoping he’d go off on his own and build his own newsletter business from scratch (he edited Phase 1 Investor and Small Cap Specialist […]
[ed. note: This is an introductory piece from longtime reader Peter Tilton, who has proposed writing a regular column for Stock Gumshoe readers about psychiatry. Not an investing topic (though the behavior of many of us in the markets may well be something that’s in need of a diagnosis), but we thought you might find […]
Has anyone tried this? A search on Gumshoe turned up nothing, but I saw articles on Motley Fool’s site as far back as 2012, pushing this. It enables you to choose your own stocks to create what is like a self-tailored ETF – you can include up to 30 stocks (and ETFs), for a single […]
[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars! You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]
[Ed. Note: Dr. KSS writes about medicine and biotech for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] Conclusion of a Series on Pain [This column is dedicated to recovery from a recent cancer diagnosis of a stuff-of-legend friend whose life I cherish. She recently […]